Skip to main content
. 2012 Feb 21;7(2):e31689. doi: 10.1371/journal.pone.0031689

Table 1. LCRMP-1 and phosphorylated GSK3β expression in relation to clinical parameters and pathological characteristics*.

LCRMP-1 p-GSK3β
Category Subcategory Number ≤50% (%) >50% (%) P ≤70% (%) >70% (%) P
Total patients 142 102 (71.8) 40 (28.2) 73 (51.4) 69 (48.6)
Sex Female 78 55 (53.9) 23 (57.5) 0.7 44 (60.3) 34 (49.3) 0.188
Male 64 47 (46.1) 17 (42.5) 29 (39.7) 35 (50.7)
Histological type Adenocarcinoma 123 86 (87.8) 37 (94.9) 0.215 60 (85.7) 63 (94.0) 0.108
Squamous cell carcinoma 14 12 (12.2) 2 (5.1) 10 (14.3) 4 (6.0)
Tumor size, cm >3 74 57 (55.9) 17 (42.5) 0.151 41 (56.2) 33 (47.8) 0.32
≤3 68 45 (44.1) 23 (57.5) 32 (43.8) 36 (52.2)
Vascular invasion Positive 25 19 (18.6) 6 (15.0) 0.61 14 (19.2) 11 (15.9) 0.613
Negative 117 83 (81.4) 34 (85.0) 59 (80.8) 58 (84.1)
Lymph node metastasis Positive 32 18 (17.7) 14 (35.0) 0.026 18 (24.7) 14 (20.3) 0.534
Negative 110 84 (82.4) 26 (65.0) 55 (75.3) 55 (79.7)
Extranodal extension Positive 20 10 (9.8) 10 (25.0) 0.019 11 (15.1) 9 (13.0) 0.729
Negative 122 92 (90.2) 30 (75.0) 62 (84.9) 60 (87.0)
Tumor stage Stage I 107 82 (80.4) 25 (62.5) 53 (72.6) 54 (78.3)
Stage II 17 13 (12.8) 4 (10.0) 11 (15.1) 6 (8.7)
Stage III–IV 18 7 (6.9) 11 (27.5) 0.004 9 (12.3) 9 (13.0) 0.505
LCRMP-1 expression, % >50 102 56 (76.7) 46 (66.7) 0.184
≤50 40 17 (23.3) 23 (33.3)
p-GSK3β expression, % >70 69 46 (45.1) 23 (57.5) 0.184
≤70 73 56 (54.9) 17 (42.5)

*P values were calculated using a two-sided chi-squared test. Abbreviations: LCRMP-1, long-form collapsin response mediator protein-1; p-GSK3β, phosphorylated Glycogen synthase kinase-3β.

Adenosquamous carcinomas are not included.